Radiology has always been a discipline of pattern recognition — the trained eye moving across an image, cataloguing what is normal, flagging what deviates. It is skilled, demanding work, and the consequences of a missed finding can be severe. Now, artificial intelligence is entering that interpretive space with tools designed not to replace the radiologist but to function as a second reader: tireless, consistent, and trained on volumes of imaging data that no human specialist could accumulate in a career. The technology is advancing quickly, the FDA clearances are accumulating, and the clinical evidence is becoming substantive enough to change how cancer is found and how early it can be caught.

Mammography was among the first imaging domains where AI demonstrated real clinical impact. The FDA has now cleared multiple AI-assisted mammography platforms, and the evidence supporting their use is meaningful. A landmark study published in The Lancet Oncology in 2023 examined AI-assisted mammography screening in Sweden and found that AI-supported reading detected 20% more cancers than standard double reading by two radiologists, while simultaneously reducing radiologist workload by approximately 44%. The AI system flagged images likely to contain cancer for priority human review, allowing radiologists to concentrate their interpretive attention where it was most needed. Crucially, the study found no significant difference in false-positive rates, addressing a concern that had been raised about AI systems generating unnecessary callbacks. These are not marginal improvements. In a disease where stage at detection is among the strongest predictors of survival, finding 20% more cancers is a clinically significant outcome.

In lung cancer, AI is being integrated into the reading of low-dose CT scans — the recommended screening modality for high-risk individuals, primarily long-term smokers between the ages of 50 and 80. Detecting and characterizing small pulmonary nodules is one of the most technically demanding tasks in thoracic radiology. Nodules smaller than six millimeters present particular interpretive challenges, and radiologist variability in nodule characterization has been a recognized source of inconsistency. AI systems trained on large CT datasets have demonstrated the ability to detect nodules with sensitivity that matches or exceeds experienced radiologists, and to assist with risk stratification — predicting which nodules are more likely to represent malignancy and warrant further workup. The practical result is better nodule management, fewer unnecessary biopsies, and more consistent identification of the early-stage cancers where surgical cure is most achievable.

It is important to understand what this technology is and what it is not. AI in radiology is a decision-support tool — it operates within a clinical workflow that is still anchored by physician judgment, clinical context, patient history, and the kind of integrative thinking that no algorithm currently replicates. The radiologist who uses an AI-assisted platform is not outsourcing a diagnosis; they are working with a tool that surfaces findings for their evaluation. False positives and false negatives remain part of the equation, and the radiologist’s role in resolving ambiguous cases is as essential as it has ever been. Regulatory clearance by the FDA does not mean infallibility — it means a device has demonstrated safety and effectiveness within defined parameters. Patients should know that AI-assisted screening is available at many major health systems, that it is not yet uniformly available across all imaging centers, and that asking whether a facility uses AI-assisted reading for mammography or lung CT is a reasonable and informed question.

The trajectory of AI in oncologic imaging points toward increasing integration, not decreasing human involvement. The most experienced radiologists in the field tend to describe the technology with a combination of enthusiasm and realism — recognizing that AI catches things fatigued humans miss, that it brings consistency to inherently variable tasks, and that its most important function may be in the enormous volume of normal or near-normal studies where human attention is a finite resource. For patients, the message is straightforward: the imaging tools used to find cancer early are getting better. Screening guidelines exist because the evidence supports them. Participating in recommended screening — and doing so at facilities using the best available tools — remains one of the most consequential decisions a person can make for their own cancer risk.